Department of Medicine, The Asthma and Allergy Center, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Clin Exp Allergy. 2010 Jun;40(6):859-66. doi: 10.1111/j.1365-2222.2010.03475.x. Epub 2010 Mar 12.
Leukolysin is a novel matrix metalloproteinase (MMP-25/MT-6) released mainly by granulocytic cells, primarily neutrophils, which are implicated in chronic airways inflammation.
To determine if leukolysin might be a serum marker for atopic asthma or chronic obstructive pulmonary disease (COPD).
Three study populations were evaluated: (1) nuclear families with medical history of atopic asthma (N=337), (2) married-in individuals from an independent study of asthma genetics (N=122) and (3) randomly selected males with diagnosis of COPD (N=100). Each person was screened for asthma or COPD symptoms, respiratory function by standardized spirometry and serum total IgE and leukolysin and anti-IL1 levels by immunoassay. Study groups (1 and 2) were also screened by skin prick test using a battery of 14 common aeroallergens. Heritability estimates for leukolysin and total IgE were made by variance components analysis.
For those without asthma or who had asthma defined as having symptoms, a physician's diagnosis and bronchial hyper-reactivity as demonstrated by reversibility in response to albuteral and/or bronchial reactivity as measured by a methacholine challenge, serum leukolysin levels were found to be higher for those with any positive skin test result. This paralleled trends for serum total IgE. In the nuclear families and COPD patients, serum leukolysin levels were significantly elevated for those who also had elevated total IgE levels (log[IgE]>2.0) compared with those with lower IgE (log[IgE]<2.0). Serum IL-1 levels correlated with the leukolycin levels. In contrast to IgE, leukolysin showed no apparent inherited component.
Among individuals with history of chronic airways inflammation (asthma and COPD) serum leukolysin may be a metabolic marker associated with chronic atopy-associated respiratory inflammation. Common factors may stimulate increased production or release of both leukolysin from myeloid cells and IgE from lymphoid cells.
白细胞溶解素是一种新型基质金属蛋白酶（MMP-25/MT-6），主要由粒细胞（主要是中性粒细胞）释放，参与慢性气道炎症。
确定白细胞溶解素是否可能成为特应性哮喘或慢性阻塞性肺疾病（COPD）的血清标志物。
评估了三个研究人群：（1）有特应性哮喘病史的核心家庭（N=337），（2）来自哮喘遗传学独立研究的已婚个体（N=122）和（3）随机选择的 COPD 诊断男性（N=100）。对每个人进行哮喘或 COPD 症状筛查、标准化肺活量测定呼吸功能以及血清总 IgE 和白细胞溶解素和抗 IL1 水平的免疫测定。研究组（1 和 2）还通过使用 14 种常见气传过敏原的皮肤点刺试验进行筛查。通过方差成分分析对白细胞溶解素和总 IgE 的遗传度进行估计。
对于那些没有哮喘或仅有哮喘症状、医生诊断、支气管高反应性（如沙丁胺醇治疗后可逆性或通过乙酰甲胆碱激发试验测量的支气管反应性）的人，发现有任何阳性皮肤试验结果的人血清白细胞溶解素水平更高。这与血清总 IgE 的趋势相似。在核心家庭和 COPD 患者中，血清白细胞溶解素水平在那些同时具有升高的总 IgE 水平（log[IgE]>2.0）的人中显著升高，而在那些 IgE 较低的人中（log[IgE]<2.0）。血清 IL-1 水平与白细胞溶解素水平相关。与 IgE 不同，白细胞溶解素没有明显的遗传成分。
在有慢性气道炎症病史的个体（哮喘和 COPD）中，血清白细胞溶解素可能是与慢性特应性相关呼吸炎症相关的代谢标志物。共同的因素可能刺激髓样细胞白细胞溶解素和淋巴样细胞 IgE 的产生或释放增加。
